PreveCeutical Medical Inc. (PRVCF) Financiero

PreveCeutical Medical, Inc. engages in licensing, branding, and marketing of nutraceutical and wellness products. The company is headquartered in West Vancouver, British Columbia. The company went IPO on 2016-12-30. The Company’s principal business activity is the development of options for preventive and curative therapies utilizing organic and nature identical products. The Company’s pipeline includes Cannabinoid Sol-Gel, Non-Addictive Analgesic, and BSV Peptide Program. Its Cannabinoid Sol-Gel is a cannabinoid-based nose-to-brain delivery system that provides relief to a range of indications from pain, inflammation, seizures, and neurological disorders. Its BSV peptide program targets cancer progression. Its nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). Its Nature Identical peptides used for treatment of various ailments. Its Dual Gene Therapy for curative and prevention therapies for diabetes and obesity.